FPT Launches FPT AI Factory to Accelerate AI Development in Japan, Offering Local Companies Pre-Orders for its NVIDIA H200 Tensor Core GPUs Cloud Service
FPT, a global leading IT firm and Preferred NVIDIA Cloud Partner (NCP), officially announced the launch of the FPT AI Factory in Japan using the full-stack NVIDIA accelerated computing platform. This flagship solution serves as a one-stop shop for AI and Cloud services, offering immense computing power for AI advancement and contributing to developing Sovereign AI in the country. Japanese customers can expedite AI development with priority access to premium solutions and features through an exclusive pre-order.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112820251/en/
Dr. Truong Gia Binh, FPT Corporation Chairman and Founder, shares FPT’s commitment to accompanying Japan in facilitating a successful AI journey (Photo: Business Wire)
At the NVIDIA AI Summit in Japan, FPT has debuted FPT AI Factory, an all-inclusive stack for end-to-end AI product lifecycle, including three main groups. FPT AI Infrastructure offers GPU cloud services with unprecedented computing power to accelerate model development and deployment. FPT AI Studio offers intelligent tools for building, pre-training, and fine-tuning AI models in depth using NVIDIA NeMo. FPT AI Inference, supported by NVIDIA NIM and NVIDIA AI Blueprints, enables customers to effectively deploy and scale their models in terms of size and number of usages. FPT AI Factory is integrated with 20+ ready-to-use AI products, built upon Generative AI, for rapid AI adoption and instant results in elevating customer experience, achieving operational excellence, transforming the human workforce, and optimizing operating expenses.
Powered by thousands of NVIDIA Hopper GPUs and next-generation ones, boosting with the latest NVIDIA AI Enterprise software platform, FPT AI Factory grants regional clientele scalable and confidential supercomputing along with essential tools to cultivate sophisticated AI technologies from scratch with faster time-to-market. This also empowers businesses to manage resources and processes expeditiously, optimizing total cost of ownership (TCO).
FPT is now accepting pre-orders for FPT AI Factory, allowing local corporate clients to leverage the diverse ecosystem of AI and Cloud, earn cloud credit, and gain early access to premium features. Combined with tailor-made consultation from seasoned AI & Cloud experts, enterprises in any industry can reinforce successful AI journeys with practical, high-value solutions.
Japan currently faces a shortage of GPU cloud solutions necessary to drive economic growth, promote innovation, and facilitate digital transformation in a secure manner. FPT’s AI-ready infrastructure in Japan provides local businesses and the government with unparalleled computational performance, high efficiency, and low-latency interactions to enrich research & development capabilities while safeguarding sensitive data and maintaining sovereignty.
By joining the NVIDIA Partner Network as a Service Delivery Partner, FPT will utilize NVIDIA's cutting-edge products and technologies to develop bespoke cloud services, hardware, software, and comprehensive integration services to drive the digital transformation in Japan.
Dr. Truong Gia Binh, FPT Corporation Chairman and Founder, affirmed, "Artificial intelligence continues to be a transformative technology for the entire world. In line with NVIDIA's global initiative, we are working closely with strategic partners to develop cloud infrastructure essential for AI applications worldwide, especially in Japan. We are committed to dedicating all necessary resources and accompanying the Japanese government, enterprises, and partners in the nation’s AI investment and development efforts. Through this significant project, we are aligning our vision and action to rapidly expand AI applications on a global scale while actualizing the collective vision of Japan and Vietnam in becoming AI nations.”
John Fanelli, NVIDIA Vice President of Enterprise AI Software, said, "In today's rapidly evolving technological landscape, Japan recognizes the importance of sovereign AI solutions for driving innovation, supporting data security, and maintaining technological independence. The FPT AI Factory built on NVIDIA accelerated computing and software represents a significant step towards meeting this need, offering Japanese companies access to cutting-edge AI infrastructure while fostering local AI development and expertise."
In April 2024, FPT publicized the development of AI Factories through a comprehensive strategic collaboration with NVIDIA. That marked a significant milestone in FPT's AI journey, aiming to promote AI research and development in the region and expand advanced AI and cloud capabilities on a global scale.
About FPT Corporation
FPT Corporation (FPT) is a global leading technology and IT services provider headquartered in Vietnam. FPT operates in three core sectors: Technology, Telecommunications, and Education. As AI is indeed a key focus, FPT has been integrating AI across its products and solutions to drive innovation and enhance user experiences within its Made by FPT ecosystem. FPT is actively working on expanding its capabilities in AI through investments in human resources, R&D, and partnerships with leading organizations like NVIDIA, Mila, AITOMATIC, and Landing AI. These efforts are aligned with FPT's ambitious goal to reach 5 billion USD in IT services revenue from global markets by 2030 and solidify its status among the world's top billion-dollar IT companies.
After nearly two decades in Japan, FPT has become one of the largest foreign-invested technology firms in the country by human resource capacity. The company delivers services and solutions to over 450 clients globally, with over 3,500 employees across 17 local offices and innovation hubs in Japan, and nearly 15,000 professionals supporting this market worldwide.
With Japan as a strategic focus for the company’s global growth, FPT has been actively expanding its business and engaging in M&A deals, such as the joint venture with Konica Minolta, strategic investment in LTS Inc, and most recently, the acquisition of NAC—its first M&A deal in the market. As digital transformation, particularly legacy system modernization viewed as a key growth driver in the Japanese market, the company is committed to providing end-to-end solutions and seamless services, utilizing advanced AI technologies as a primary accelerator. For more information, please visit https://fpt.com/en.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112820251/en/
Contacts
Media
Mai Duong (Ms.)
FPT Software
PR Manager
MCP.PR@fpt.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom